Novavax reported $-208632000 in EBIT for its first fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Adamas Pharmaceuticals ADMS:US -9525000 5.45M
Adma Biologics ADMA:US $ -15164250 2.06M
Agenus AGEN:US $ -41371000 16.23M
Astrazeneca AZN:US 1.4B 366M
AstraZeneca AZN:LN 1.4B 366M
Biocryst Pharmaceuticals BCRX:US $ -51377000 1.03M
BioSpecifics Technologies BSTC:US 651.19K 676.28K
Dynavax Technologies DVAX:US $ 29.01M 40.65M
Genocea Biosciences GNCA:US $ -14546000 2.12M
Geron GERN:US $ -28454000 5.19M
GlaxoSmithKline GSK:LN 1.96B 281M
Kindred Biosciences KIN:US -9166000 864K
Mannkind MNKD:US $ -10029000 9.71M
Merk MRK:US $ 3930M 332M
Minerva Neurosciences NERV:US $ -8963290 1.46M
Moderna Inc MRNA:US 1.27B 1.54B
Novartis NVS:US 3.4B 415M
Novavax NVAX:US $ -208632000 25.78M
Pain Therapeutics PTIE:US $ -3533000 909K
Peregrine Pharmaceuticals PPHM:US $ 3.09M 904K
Pfizer PFE:US $ 6662M 905M
Sarepta Therapeutics SRPT:US $ -141865000 28.85M
Tg Therapeutics TGTX:US $ -77492000 11.71M